Compare Mesoblast Limited (MESO) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ServiceNow Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while ServiceNow Inc trades at $139.4 (market cap $142.54B). The key difference: ServiceNow Inc is far larger — about 78.8× Mesoblast Limited's market cap, and ServiceNow Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and ServiceNow Inc for 54 Days on average.
| MESO | NOW | |
|---|---|---|
Market Cap | $1.81B | $142.54B |
Volume | 240,620 | 8,001,761 |
Sector | Health | Technology |
52-Week High | $20.96 | $189.26 |
52-Week Low | $13.19 | $83.00 |
Typical Hold Time | 14 Days | 54 Days |
Enterprise Value | $1.89B | $146.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
ServiceNow (NOW) trades at $139.75, up 1.29% with bullish technical momentum and strong institutional support. The company demonstrates robust revenue growth from $7.2B in 2022 to $13.3B in 2025, with consistent earnings beats and expanding AI capabilities driving investor optimism. Despite premium valuation metrics (P/E 86.17, P/S 9.75), the stock benefits from positive analyst sentiment with 87% buy ratings and a $146.04 consensus target.
NOW presents a compelling growth story with AI revenue surpassing $1B and projected to triple by 2029. However, elevated valuation multiples and competitive pressures from Atlassian and Palantir warrant caution. The stock's upside depends on sustained AI adoption and margin preservation amid increasing investment requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
